Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
AssigneeDyax Corp.
InventorsHenry Blair, Thomas Beck, Robert Ladner
Life of this patent
Estimating the term…
Abstract
Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
Claims32
A method for preventing or reducing blood loss in a patient comprising administering to the patient a non-naturally occurring kallikrein inhibitor polypeptide in combination with an anti-thrombolytic agent.
A method for preventing or reducing the onset of systemic inflammatory response associated with a surgical procedure in a patient comprising administering to the patient a non-naturally occurring kallikrein inhibitor polypeptide and an anti-thrombolytic agent.
A method for preventing or reducing cerebral ischemia in a patient, comprising:
- administering to the patient a non-naturally occurring kallikrein inhibitor polypeptide in combination with an anti-thrombolytic agent.
A method for preventing or reducing reperfusion injury in a patient, the method comprising administering to the patient a non-naturally occurring kallikrein inhibitor polypeptide in combination with an anti-thrombolytic agent.
Dependencies are inferred from the claim text.